CRISPR-U™ Cell Line
CRISPR-U™ (based on CRISPR/Cas9 technology), developed by
Ubigene, is more efficient than general CRISPR/Cas9 in double-strand breaking, and CRISPR-U™ can greatly improve
the efficiency of homologous recombination, easily achieve
knockout (KO),
point mutation (PM) and
knockin (KI) in vitro and in vivo. With
CRISPR-U, Ubigene has successfully edit genes on more than 100 cell lines.
CRISPR/Cas9 recognizes the target sequence with gRNA, and guide Cas9 endonuclease to cut
the upstream of PAM, resulting in the double-strand break (DSB) of the target site DNA. To repair the DSB, the
cell uses its own DNA repair mechanism to add or delete or replace pieces of DNA sequences via Homology Directed
Repair (HDR) or Non-Homologous End Joining (NHEJ).
Close CRISPR-U™ (based on CRISPR/Cas9 technology), developed by Ubigene, is more
efficient than general CRISPR/Cas9 in double-strand breaking, and CRISPR-U™ can greatly improve the efficiency of
homologous recombination, easily achieve
Urinary System Human bladder carcinoma cell line (TCCSUP)
Human bladder carcinoma cell line (5637)
Human
Bladder Transitional Cell Carcinoma Cell Line (T24)
Human Embryonic Kidney Cell Line(HEK293)
Human Embryonic Kidney Cell Line(293T)
Human prostate carcinoma cell line (22RV1)
Madin-Darby
Canine Kidney Cell Line (MDCK)
Distal nephron cell line (Distal nephron cell line（JU4s）)
Blood and Lymphatic System Mouse Macrophage Cell Line (RAW264.7)
Porcine Alveolar Macrophage Cell Line (3D4/21)
Human
Monocytic Cell Line (THP-1)
Rat Basophil Leukemia Cell Line (RBL-2H3)
Human leukemia cell line
(HL-60)
Human T lymphocyte cell line (Jurkat, Clone E6-1)
Human myelogenous leukemia cell line
(K-562)
Human caucasian histiocytic lymphoma cell line (U-937)
Human Acute Non-B Non-T
Lymphocytic Leukemia Cell Line (Reh)
Human B Cell Lymphoma Cancer Cell Line U2932
Respiratory System Human Lung Cancer Cell Line (A549)
Human Lung Cancer Cell Line (Calu-1)
Human Lung Squamous
Carcinoma Cell Line (NCI-H520)
Lewis lung carcinoma (LLC)
Human Lung Cancer Cell Line
(SK-MES-1)
Human Lung Squamous Cell Carcinoma Cell Line NCI-H226
Human Non-small Cell Lung
Carcinoma Cell Line (NCI-H1299)
Human Non-small Cell Lung Carcinoma Cell Line (HCC827)
Human
Small Cell Lung Cancer Cell Line H69AR
Human Bronchial Epithelial Cell Line (BEAS-2B)
Human
Bronchial Epithelial Cell Line (16HBE)
Human hypopharyngeal carcinoma cell line (FaDu)
Chinese
hamster lung cells (V79)
Endocrine System Human Breast Cancer Cell Line (MDA-MB-231)
Human Breast Cancer Cell Line (MDA-MB-468)
Human
Breast Cancer Cell Line (MDA-MB-453)
Human Breast Cancer Cell Line (MDA-MB-436)
Human Breast
Cancer Cell Line (ZR-75-1)
Human Breast Epithelial Cell Line (HBL-100)
Human Breast Cancer Cell
Line (MCF7)
Mouse Breast Cancer Cell Line (4T1)
Human Pancreatic Carcinoma Cell Line
(PANC-1)
Human Breast Cancer Cell Line (JIMT-1)
Human breast cancer cell line (MCF-7)
Human Breast Adenocarcinoma Cell Line (SK-BR-3)
Human Metastatic Pancreatic Adenocarcinoma Cell Line
(AsPC-1)
Mouse Pancreatic Cancer Cell Line (Pan02)
Murine Breast Cancer Cell Line (E0771)
Human Pancreatic Carcinoma Cell Line (MIA PaCa-2)
Human prostate cancer cell line (PC3)
Human
Prostate Cancer Cell Line (VCaP)
Mouse Acinar Pancreatic Cell Line (266-6)
Human pancreatic
cancer cell line (BxPC-3)
Human Breast Adenocarcinoma Cell Line (T-47D)
Circulatory System Rat Cardiac Myocytes (H9C2)
Mouse Cardiac Muscle Cell Line (HL-1)
Human Coronary Artery
Endothelial Cell line (HCAEC)
Mouse Myoblast Cell Line (C2C12)
Digestive System Human Colon Cancer Cell Line (HCT116)
Human Colon Cancer Cell Line (SW480)
Human Colon Cancer
Cell Line (SW620)
Human Colon Cancer Cell Line (HT-29)
Human Colon Cancer Cell Line (LoVo)
Human colon carcinoma cell line (RKO)
Human caucasian colon adenocarcinoma cell line (COLO 205)
Murine Colorectal Carcinoma Cell Line (MC38)
Murine colorectal carcinoma cell line (CT26.WT)
Human colon adenocarcinoma cell line (DLD-1)
Human colorectal adenocarcinoma cell line
(NCI-H716)
Human colorectal adenocarcinoma cell line (Caco-2)
Human colon carcinoma cell line
(T84)
Human Liver Cell Line (L-02)
Human liver cancer cell line (Hep G2)
Human Hepatoma
Cell Line (Hep 3B)
Human hepatocellular carcinoma cell line (HuH-7)
Human Hepatocellular
Carcinoma Cell Line (SNU-387)
Human Hepatocarcinoma Cell Line (SMMC-7721)
Mouse Hepatoma Cell
Line (H22)
Mouse Hepatoma Cell Line (Hepa 1-6)
Human hepatobiliary cancer cell line (RBE)
Human Gastric Cancer Cell Line (HGC-27)
Human Gastric Cancer Cell Line (SGC-7901)
Human Gastric
Cancer Cell Line (MGC80-3)
Human gastric cancer cell line (AGS)
Human Esophageal Squamous
Carcinoma Cell Line (KYSE-150)
Human Esophageal Squamous Carcinoma Cell Line (KYSE-30)
Human
renal cell carcinoma cell line (786-o)
African green monkey kidney cell (Vero)
Human Renal Cell
Carcinoma Cell Line (ACHN)
Skeleton, Articulus, Soft Tissue, Derma System Human Osteosarcoma Cell Line (MG63)
Human bone osteosarcoma epithelial cell line (U-2 OS)
Human
fibrosarcoma cell line (HT1080)
Human malignant melanoma cell line (A-375)
Human Melanoma Cell
Line (M14)
Murine melanoma cell line (B16-F10)
Human Epidermoid Carcinoma Cell Line (A431)
Mouse myeloma cell line (Sp2/0-Ag14)
Mouse Skin Cancer Cell Line (SCC7)
Immortalized
Ameloblastoma Cells (hTERT-AM)
Ocular, Otolaryngologic and Oral System Rat Muller Cell Line (rmc-1)
Human Nasopharyngeal Carcinoma Cell Line (NPC-43)
Human
Nasopharyngeal Carcinoma Cell Line (cne2z)
Human Nasopharyngeal Carcinoma Cell Line (CNE-1)
Brain and Nervous System Human Neuroblastoma Cell Line (SK-N-SH)
Human Neuroblastoma Cell Line (SH-SY5Y)
Mouse
neuroblastoma cell line (Neuro-2a)
Human Glioblastoma Cell Line (U251)
Rat Glioblastoma Cell
Line (C6)
Mouse Glioblastoma Cell Line (GL261)
Mouse Microglial Cell Line (BV2)
Human
glioblastoma cell line (U-87 MG)
Mouse Anterior Parietal Bone Cell Line (MC3T3-E1 Subclone 14)
Human Microvascular Endothelial Cell Line (hCMECD3)
Immortalize Human Microvascular Endothelial Cell
Line (hCMEC/D3)
Mouse Hippocampal Neuron Cell Line (HT22)
Reproductive System Human Cervical Carcinoma Cell Line (HeLa)
Human Cervical Carcinoma Cell Line (Hela 229)
Human
Cervical Squamous Cell Line (SiHa)
Mouse Embryonic Fibroblasts (NIH/3T3)
Chinese Hamster Ovary
Cell Line (CHO-K1)
Human Ovarian Cancer Cell Line (SK-OV-3)
Human Ovarian Cancer Cell Line
(OVCAR3)
Human Choriocarcinoma Cell Line (BeWo)
Human Ovarian Cancer Cell Line (CAOV3)
Human Trophoblast Cell Line (HTR-8/SVneo)
Mouse Pituitary Gonadotrope Cell Line (Lbetat2)
Mouse
Testicular Stromal Cell Line (TM3)
Technical advantage
Exclusive innovation, 10 times more efficient in gene-editing.
Successfully edit genes on more than 100 types of cell lines.
Easily generate knockout (KO), point mutation (PM) and knockin (KI) in vitro and in vivo.
CRISPR-U™ offers a 100% mutation guarantee. No mutation, no charge!
Point Mutation Cell
Lines
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC. A) Genomic sequence
surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition site containing 20 bp (yellow);
CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink). B) ssODN with 120 bp,
60 bp upstream and 60 bp downstream the mutation site containing the WT nucleotide (C, green).
Point mutation Strategy
Work Flow and Validation
Case Study
The A79V mutation of PSEN1 gene can cause Alzheimer's disease. Somatic cells of patients with
Alzheimer's disease are induced into pluripotent stem cells (iPSCs), and then the mutant gene is modified by
replacing the point mutation with a wild-type sequence. By studying the iPSC of patients and the modified iPSC, we
can know the effect of the mutation on cell phenotype, so as to further study the pathological effect of the
mutation.
CRISPR/Cas9 and ssODN used to repair the point mutation in A79V-hiPSC.
A) Genomic
sequence surrounding the mutation site: mutated nucleotide (T, red); sgRNA recognition site containing 20 bp
(yellow); CRISPR cutting site between the 17th and 18th bp (bold); forward and reverse primers (pink).
B)
ssODN with 120 bp, 60 bp upstream and 60 bp downstream the mutation site containing the WT nucleotide (C,
green).
B. Sequencing of exon 4 of the PSEN1 gene in hiPSCs.
A) Heterozygous c.236C>T
substitution in the mother line previously published.
B) Successful correction of the point mutation
(T>C).
Reference：
Fukuda, N., Senga, Y., & Honda, S. (2019). Anxa2‐and Ctsd‐knockout CHO cell lines to
diminish the risk of contamination
with host cell proteins. Biotechnology progress, e2820.
Subscribe Us
Gene Editing Services
EZ-editor™
Red Cotton Gene knockout Project
